Immunocore Missed Expectations

Immunocore (IMCR) reported a loss of $0.20 per share on revenue of $97.96 million for the second quarter ended June 2025. The consensus estimate was a loss of $0.21 per share on revenue of $92.64 million. The Earnings Whisper number was a loss of $0.19 per share. The company missed expectations by 5.26% while revenue grew 29.93% on a year-over-year basis.

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune.